These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32449962)

  • 1. Acute systemic reactions to sublingual immunotherapy for house dust mite.
    Janssens NS; van Ouwerkerk L; Gerth van Wijk R; Karim F
    Allergy; 2020 Nov; 75(11):2962-2963. PubMed ID: 32449962
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis.
    Demoly P; Kleine-Tebbe J; Rehm D
    Allergy; 2017 Oct; 72(10):1576-1578. PubMed ID: 28273339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sublingual immunotherapy (SLIT) for house dust mite - when to take a break?: An unusual reaction to SLIT post vaccinations.
    Gallagher A; Trujillo J
    Ann Allergy Asthma Immunol; 2023 Jun; 130(6):809-810. PubMed ID: 36924938
    [No Abstract]   [Full Text] [Related]  

  • 4. Improvements with sublingual house dust mite immunotherapy in allergic rhinitis.
    Lipworth B
    J Allergy Clin Immunol; 2016 Aug; 138(2):634-5. PubMed ID: 27233152
    [No Abstract]   [Full Text] [Related]  

  • 5. A Three-Year Course of House Dust Mite Sublingual Immunotherapy Appears Effective in Controlling the Symptoms of Allergic Rhinitis.
    Novakova SM; Novakova PI; Yakovliev PH; Staevska MT; Mateva NG; Dimcheva TD; Peichev JL
    Am J Rhinol Allergy; 2018 May; 32(3):147-152. PubMed ID: 29649893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of the standardized quality house dust mite sublingual immunotherapy tablet in real life: A noninterventional, open-label study.
    Reiber R; Wolf H; Futschik T; Schwab JA; Hölscher U; Schnitker J; Wüstenberg E
    J Allergy Clin Immunol Pract; 2021 Aug; 9(8):3221-3223.e5. PubMed ID: 33839345
    [No Abstract]   [Full Text] [Related]  

  • 7. Odactra--sublingual immunotherapy for house dust mite-induced allergic rhinitis.
    Med Lett Drugs Ther; 2018 Feb; 60(1541):37-39. PubMed ID: 29485977
    [No Abstract]   [Full Text] [Related]  

  • 8. The SQ House Dust Mite SLIT-Tablet Is Well Tolerated in Patients with House Dust Mite Respiratory Allergic Disease.
    Emminger W; Hernández MD; Cardona V; Smeenk F; Fogh BS; Calderon MA; de Blay F; Backer V
    Int Arch Allergy Immunol; 2017; 174(1):35-44. PubMed ID: 28950268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early increase in serum specific IgG2 upon allergen immunotherapy with a 300 IR sublingual house dust mite tablet.
    Berjont N; Floch VVB; O'Hehir RE; Canonica WG; van Zelm MC; Batard T; Mascarell L
    Allergy; 2023 Jul; 78(7):2040-2043. PubMed ID: 36809660
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
    Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
    J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from subcutaneous to sublingual immunotherapy during the maintenance phase in patients with house dust mite allergy.
    Kiatiwat P; Sangasapaviliya A; Pradubpongsa P; Sangkanjanavanich S; Chiewchalermsri C; Jacquet A; Jaisupa N; Jindarat S; Boonpiyathad T; Mitthamsiri W
    Allergy; 2023 Jul; 78(7):2019-2021. PubMed ID: 36754574
    [No Abstract]   [Full Text] [Related]  

  • 12. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
    Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F
    J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sublingual immunotherapy in patients with house dust mite allergic rhinitis: prospective study of clinical outcomes over a two-year period.
    Soh JY; Thalayasingam M; Ong S; Loo EX; Shek LP; Chao SS
    J Laryngol Otol; 2016 Mar; 130(3):272-7. PubMed ID: 26781592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rare adverse events due to house dust mite sublingual immunotherapy in pediatric practice: two case reports.
    Galip N; Bahceciler N
    Immunotherapy; 2015; 7(12):1235-9. PubMed ID: 26427747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. House dust mite sublingual immunotherapy in allergic rhinitis.
    Cho SW; Han DH; Kim JW; Kim DY; Rhee CS
    Immunotherapy; 2018 Jun; 10(7):567-578. PubMed ID: 29562802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of a 300 IR house dust mite sublingual tablet: descriptive 4-year final analysis of a post-marketing surveillance in Japan.
    Okamoto Y; Kato M; Ishii K; Sato Y; Hata T; Asaka Y
    Immunotherapy; 2023 Nov; 15(16):1401-1414. PubMed ID: 37727966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.
    Mosbech H; Canonica GW; Backer V; de Blay F; Klimek L; Broge L; Ljørring C
    Ann Allergy Asthma Immunol; 2015 Feb; 114(2):134-40. PubMed ID: 25624131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of immunotherapy on quality of life in patients with house dust mite allergic rhinitis.
    Pedregal-Mallo D; Pacheco E; Rodrigo JP; Llorente JL; Alvarez-Marcos C
    Allergy; 2020 Jul; 75(7):1783-1785. PubMed ID: 32020620
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.
    Maloney J; Prenner BM; Bernstein DI; Lu S; Gawchik S; Berman G; Kaur A; Li Z; Nolte H
    Ann Allergy Asthma Immunol; 2016 Jan; 116(1):59-65. PubMed ID: 26553448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of serum vitamin D concentration with humoral-specific IgG2 and IgG4 levels in high responders to immunotherapy with a 300 IR sublingual house dust mite tablet.
    Fernandez JC; Luce S; Floch VB; Canonica WG; Batard T; Mascarell L
    Clin Exp Allergy; 2022 Oct; 52(10):1219-1224. PubMed ID: 35861410
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.